LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own1.30% Shs Outstand149.15M Perf Week-4.43%
Market Cap284.50M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float143.38M Perf Month10.86%
Income-90.30M PEG- EPS next Q-0.16 Inst Own83.80% Short Float3.80% Perf Quarter-7.18%
Sales0.30M P/S948.34 EPS this Y-14.00% Inst Trans-0.96% Short Ratio8.10 Perf Half Y-53.48%
Book/sh0.62 P/B3.13 EPS next Y12.90% ROA-58.50% Target Price18.00 Perf Year-55.50%
Cash/sh0.59 P/C3.29 EPS next 5Y- ROE-75.20% 52W Range1.31 - 6.33 Perf YTD-50.76%
Dividend- P/FCF- EPS past 5Y13.80% ROI-76.70% 52W High-69.35% Beta1.38
Dividend %- Quick Ratio- Sales past 5Y-67.30% Gross Margin- 52W Low48.09% ATR0.20
Employees87 Current Ratio4.70 Sales Q/Q-93.00% Oper. Margin- RSI (14)53.91 Volatility16.00% 10.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.70% Profit Margin- Rel Volume1.69 Prev Close1.86
ShortableYes LT Debt/Eq0.25 EarningsMay 05 BMO Payout- Avg Volume672.06K Price1.94
Recom2.30 SMA2010.26% SMA508.49% SMA200-41.14% Volume1,137,346 Change4.30%
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Jun-29-22 04:01PM  
Jun-06-22 02:16PM  
Jun-01-22 08:00AM  
May-31-22 08:00AM  
May-11-22 06:35AM  
May-05-22 06:00AM  
Apr-29-22 08:00AM  
Apr-07-22 08:00AM  
Apr-04-22 08:00AM  
Apr-02-22 12:15PM  
Mar-21-22 08:01AM  
Mar-18-22 09:57AM  
Mar-17-22 04:14PM  
Mar-08-22 04:34AM  
Mar-04-22 05:10AM  
Mar-03-22 06:21PM  
Feb-28-22 04:54PM  
06:01AM  
06:00AM  
Feb-25-22 09:03PM  
Jan-13-22 09:00AM  
Jan-04-22 04:05PM  
Jan-03-22 10:46AM  
Dec-30-21 04:05PM  
Nov-15-21 04:30PM  
Nov-14-21 08:35AM  
Nov-09-21 08:00AM  
Nov-03-21 04:02PM  
Nov-01-21 11:33AM  
Oct-28-21 07:28PM  
Oct-06-21 04:28AM  
Sep-15-21 08:00AM  
Aug-30-21 07:00AM  
Aug-23-21 09:45AM  
06:09AM  
Jul-30-21 08:35AM  
07:01AM  
07:00AM  
Jul-28-21 05:40PM  
Jul-22-21 03:03PM  
Jun-25-21 08:00AM  
May-26-21 04:15PM  
May-13-21 04:15PM  
May-06-21 08:35PM  
04:05PM  
May-03-21 06:02AM  
Apr-29-21 04:14PM  
Apr-19-21 12:30PM  
Apr-08-21 04:35PM  
Mar-15-21 08:36AM  
Mar-10-21 05:55PM  
04:10PM  
02:15PM  
Mar-04-21 04:05PM  
12:30PM  
Mar-03-21 12:40PM  
Mar-02-21 10:02AM  
Mar-01-21 10:33AM  
Feb-26-21 10:13AM  
Feb-11-21 11:05AM  
Feb-06-21 06:55AM  
Jan-31-21 02:55AM  
Jan-29-21 06:56AM  
Jan-22-21 10:18AM  
Jan-20-21 12:13PM  
Jan-15-21 08:31AM  
Jan-14-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 09:40AM  
Dec-31-20 08:00AM  
06:11AM  
Dec-16-20 04:05PM  
Dec-12-20 04:03PM  
Dec-11-20 06:04PM  
08:02AM  
07:38AM  
Dec-09-20 09:22AM  
Nov-16-20 10:02PM  
08:00AM  
Nov-06-20 07:48AM  
Oct-29-20 10:05AM  
08:02AM  
06:00AM  
06:00AM  
Oct-27-20 08:00AM  
Sep-23-20 06:43PM  
Sep-14-20 09:46AM  
Sep-08-20 04:05PM  
Sep-04-20 08:00AM  
Sep-03-20 06:00PM  
Aug-24-20 11:35AM  
Aug-10-20 11:52AM  
Aug-03-20 07:25AM  
Aug-02-20 09:54AM  
Jul-30-20 06:00PM  
03:52PM  
10:55AM  
07:15AM  
07:10AM  
07:00AM  
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swain Judith LDirectorApr 30Option Exercise0.004,024031,030May 02 04:22 PM
SOBECKI CHRISTOPHER JDirectorApr 30Option Exercise0.004,0240149,721May 02 04:18 PM
NIES ALAN SDirectorApr 30Option Exercise0.004,024031,744May 02 04:16 PM
Palantoni FrankDirectorApr 30Option Exercise0.004,024031,030May 02 04:17 PM
LEFKOWITZ ROBERT J MDDirectorApr 30Option Exercise0.004,024031,030May 02 04:15 PM
DEBBANE RAYMONDDirectorApr 30Option Exercise0.004,0240331,545May 02 04:14 PM
Amouyal PhilippeDirectorApr 30Option Exercise0.004,024031,030May 02 04:11 PM
BARKER SAM LDirectorApr 30Option Exercise0.004,024070,315May 02 04:12 PM